Innate Pharma SA Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Jul 7, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jul 7, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, regulatory-update
TL;DR
Innate Pharma SA filed a 6-K on July 7th with a press release from July 4th.
AI Summary
Innate Pharma SA filed a Form 6-K on July 7, 2025, reporting information as of July 4, 2025. The filing includes a press release dated July 4, 2025, as Exhibit 1.1. Innate Pharma SA is a foreign private issuer based in Marseille, France, and files annual reports under Form 20-F.
Why It Matters
This filing provides an update from Innate Pharma SA, potentially containing important business or financial information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate indication of significant new risks.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 001-39084 (company) — SEC File Number
- July 4, 2025 (date) — Date of Press Release
- July 7, 2025 (date) — Filing Date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report information as of July 4, 2025, and to include a press release dated July 4, 2025, as an exhibit.
What is the filing date of this Form 6-K?
The Form 6-K was filed on July 7, 2025.
What is the company's principal executive office located?
The company's principal executive office is located at 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma SA file annual reports under Form 20-F or 40-F?
Innate Pharma SA files annual reports under Form 20-F.
What is the SEC file number for Innate Pharma SA?
The SEC file number for Innate Pharma SA is 001-39084.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 7, 2025 regarding Innate Pharma SA (IPHYF).